Cingulate, Indegene to Participate in Benzinga All Live Access Event

KANSAS CITY, Kan., May 12, 2023 (GLOBE NEWSWIRE) — Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced that Cingulate Chairman & CEO Shane J. Schaffer, and Timothy Moore, Indegene Senior Vice President, Emerging Biotech, will participate in a live Benzinga All Access event on Monday May 15, 2023, at 10 a.m. CST.

The discussion will focus on the recent announcement of a joint commercialization agreement between Cingulate and Indegene, a life sciences commercialization company, to provide commercial support for Cingulate’s lead candidate CTx-1301 (dexmethylphenidate), a novel, investigational treatment being developed as a true, once-daily stimulant medication for attention deficit/hyperactivity disorder (ADHD), upon approval from the U.S. Food and Drug Administration (FDA).

The event may be viewed live on Benzinga’s YouTube channel, Benzinga All Access, and will also be available for viewing on Cingulate’s website at cingulate.com/investors.

About Cingulate® 
Cingulate Inc. (NASDAQ: CING), is a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. With an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD), Cingulate is identifying and evaluating additional therapeutic areas where PTR technology may be employed to develop future product candidates, including to treat anxiety disorders. Cingulate is headquartered in Kansas City. For more information visit Cingulate.com

About Indegene
We are a digital-first, life sciences commercialization company. We help biopharmaceutical, emerging biotech and medical device companies develop products, get them to the market, and grow their impact through the life cycle in a more effective, efficient, and modern way. We bring together healthcare domain expertise, fit-for-purpose technology, and an agile operating model to provide a diverse range of solutions. These aim to deliver, amongst other outcomes, a personalized, scalable and omnichannel experience for patients and physicians. It’s what drives our team and our purpose to enable healthcare organizations to be future ready. To learn more, please visit www.indegene.com

Investor Relations 
Thomas Dalton 
Vice President, Investor & Public Relations, Cingulate
tdalton@cingulate.com
913-942-2301

Matt Kreps
Darrow Associates
mkreps@darrowir.com
214-597-8200

Media Relations
Melyssa Weible
Elixir Health Public Relations
mweible@elixirhealthpr.com
201-723-5805

Staff

Recent Posts

Harmonic, Backed by Robinhood CEO Vlad Tenev, Announces Development of Mathematical Superintelligence Platform

AI Model Designed to Guarantee Accuracy & Avoid HallucinationsPALO ALTO, Calif.--(BUSINESS WIRE)--Harmonic, an artificial intelligence…

2 hours ago

HealthPartners Institute receives $3.2M grant from National Cancer Institute to create and study new tool that will improve care for patients with genetic risk of cancer

The project, which leverages HealthPartners myGenetics community research database, will help primary care clinicians provide…

2 hours ago

Drug Discovery Informatics Market Size to Grow USD 1 Million by 2030 at a CAGR of 9% | Valuates Reports

BANGALORE, India, June 10, 2024 /PRNewswire/ -- Drug Discovery Informatics Market is Segmented by Type (Software, Services), by…

2 hours ago

Special Touch Home Care Launches New Website Dedicated to Consumer Directed Personal Assistance Services

Commemorating 40 years of providing exceptional home health care, Special Touch Home Care launches www.CDPAS.com geared…

2 hours ago